Microperimetry and mfERG as functional measurements in diabetic macular oedema undergoing intravitreal ranibizumab treatment.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
03
02
2020
accepted:
17
06
2020
revised:
15
06
2020
pubmed:
4
7
2020
medline:
9
7
2021
entrez:
4
7
2020
Statut:
ppublish
Résumé
To evaluate Microperimetry (MP) and multifocal electroretinogram (mfERG) as whole-macula functional markers of treatment response in naive diabetic macular oedema (DMO) patients undergoing ranibizumab treatment. An exploratory sub-analysis of a prospective study (NCT01947881-CHARTRES). Patients received three monthly ranibizumab injections (loading dose) followed by pro re nata (PRN) regimen during 1 year. At baseline, during and after treatment (Months 0, 3, 6 and 12), subjects were tested using BCVA, OCT, MP and mfERG. MP was performed in the central 12°, and retinal sensitivity was measured overall (mean sensitivity (MS)), and in three concentric rings (R1-R3). mfERG P1 amplitude and implicit time were measured over six concentric rings (R1-R6). Thirty-two eyes were included. MP mean and rings sensitivity were significantly lower in DMO (p < 0.001). After loading dose, a significant improvement in retina sensitivity was observed, particularly in good BCVA responders (MS = +2.28 dB; R1 = +2.33 dB, R2 = +2.20 dB, R3 = +2.25 dB; p = 0.049). Overall retinal sensitivity was significantly correlated with BCVA improvement (r = 0.54; p = 0.026) and inversely correlated with OCT central subfield thickness improvement (r = -0.39; p = 0.026). mfERG amplitude and implicit time were also lower in DMO (p < 0.011). An improvement of mfERG P1 amplitude and implicit time in R1 was noted in good responders after ranibizumab loading dose (+16.49 nV/deg Microperimetry and mfERG were able to demonstrate DMO functional improvement after treatment loading dose, as well as early visual changes when treatment regimen was switched to PRN.
Identifiants
pubmed: 32616867
doi: 10.1038/s41433-020-1054-2
pii: 10.1038/s41433-020-1054-2
pmc: PMC8182789
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Ranibizumab
ZL1R02VT79
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1384-1392Références
Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England & Wales. BMC Public Health. 2006;6:58.
pubmed: 16524463
pmcid: 1420283
doi: 10.1186/1471-2458-6-58
Heier JS, Korobelnik J-F, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123:2376–85.
pubmed: 27651226
doi: 10.1016/j.ophtha.2016.07.032
Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmol. 2011;118:615–25.
doi: 10.1016/j.ophtha.2011.01.031
Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase iii randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.
pubmed: 22330964
doi: 10.1016/j.ophtha.2011.12.039
Csaky KG, Richman EA, Ferris FL. Report from the NEI/FDA ophthalmic clinical trial design and endpoints symposium. Investig Ophthalmol Vis Sci. 2008;49:479–89.
doi: 10.1167/iovs.07-1132
Ranibizumab (Lucentis): Visual Impairment due to Choroidal Neovascularization Secondary to Pathologic Myopia. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015. https://pubmed.ncbi.nlm.nih.gov/26962598/
Beck RW, Maguire MG, Bressler NM, Glassman AR, Lindblad AS, Ferris FL. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology. 2007;114:1804–9.
pubmed: 17908590
doi: 10.1016/j.ophtha.2007.06.047
Chakravarthy U, Pearce I, Banerjee S, Burton BJL, Downey L, Gale R, et al. Patient-reported outcomes in the RELIGHT clinical trial of ranibizumab in diabetic macular oedema. BMJ Open Ophthalmol. 2019;4:1–8.
doi: 10.1136/bmjophth-2018-000226
Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Nakamura M. New insights into the pathophysiology of diabetic retinopathy: potential cell-specific therapeutic targets. Diabetes Technol Ther. 2000;2:601–8.
pubmed: 11469624
doi: 10.1089/15209150050502023
Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:283–90.
pubmed: 12657367
doi: 10.1016/S0278-5846(03)00023-X
Jackson GR, Barber AJ. Visual dysfunction associated with diabetic retinopathy. Curr Diabetes Rep. 2010;10:380–4.
doi: 10.1007/s11892-010-0132-4
Santos AR, Ribeiro L, Bandello F, Lattanzio R, Egan C, Frydkjaer-Olsen U, et al. Functional and structural findings of neurodegeneration in early stages of diabetic retinopathy: cross-sectional analyses of baseline data of the EUROCONDOR project. Diabetes. 2017;66:2503–10.
pubmed: 28663190
doi: 10.2337/db16-1453
Yohannan J, Bittencourt M, Sepah YJ, Hatef E, Sophie R, Moradi A, et al. Association of retinal sensitivity to integrity of photoreceptor inner/outer segment junction in patients with diabetic macular edema. Ophthalmology. 2013;120:1254–61.
pubmed: 23499060
doi: 10.1016/j.ophtha.2012.12.003
Shen Y, Liu K, Xu X. Correlation between visual function and photoreceptor integrity in diabetic macular edema: spectral-domain optical coherence tomography. Curr Eye Res. 2016;41:391–9.
pubmed: 25897822
doi: 10.3109/02713683.2014.997887
Wang J, Jie C, Tao Y, Meng N, Hu Y, Wu Z. Macular integrity assessment to determine the association between macular microstructure and functional parameters in diabetic macular edema. Int J Ophthalmol. 2018;11:1185–91.
pubmed: 30046537
pmcid: 6048347
Sutter EE, Tran D. The field topography of ERG components in man–I. The photopic luminance response. Vis Res. 1992;32:433–46.
pubmed: 1604830
doi: 10.1016/0042-6989(92)90235-B
Han Y, Adams AJ, Bearse MA, Schneck ME. Multifocal electroretinogram and short-wavelength automated perimetry measures in diabetic eyes with little or no retinopathy. Arch Ophthalmol. 2004;122:1809–15.
pubmed: 15596584
doi: 10.1001/archopht.122.12.1809
Schneck ME, Bearse MA, Han Y, Barez S, Jacobsen C, Adams AJ. Comparison of mfERG waveform components and implicit time measurement techniques for detecting functional change in early diabetic eye disease. Doc Ophthalmol. 2004;108:223–30.
pubmed: 15573946
doi: 10.1007/s10633-004-8745-z
Tehrani NM, Riazi-Esfahani H, Jafarzadehpur E, Mirzajani A, Talebi H, Amini A, et al. Multifocal electroretinogram in diabetic macular edema; correlation with visual acuity and optical coherence tomography. J Ophthalmic Vis Res. 2015;10:165–71.
pubmed: 26425320
pmcid: 4568615
doi: 10.4103/2008-322X.163773
Greenstein VC, Chen H, Hood DC, Holopigian K, Seiple W, Carr RE. Retinal function in diabetic macular edema after focal laser photocoagulation. Investig Ophthalmol Vis Sci. 2000;41:3655–64.
Bearse MA, Ozawa GY. Multifocal electroretinography in diabetic retinopathy and diabetic macular edema. Curr Diabetes Rep. 2014;14:526.
doi: 10.1007/s11892-014-0526-9
Santos AR, Costa MÂ, Schwartz C, Alves D, Figueira J, Silva R, et al. Optical coherence tomography baseline predictors for initial best-corrected visual acuity response to intravitreal anti-vascular endothelial growth factor treatment in eyes with diabetic macular edema: the CHARTRES Study. Retina. 2018;38:1110–9.
pubmed: 28613220
doi: 10.1097/IAE.0000000000001687
Hood DC, Bach M, Brigell M, Keating D, Kondo M, Lyons JS, et al. ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 edition). Doc Ophthalmol. 2012;124:1–13.
pubmed: 22038576
doi: 10.1007/s10633-011-9296-8
Elman MJ, Ayala A, Bressler NM, Browning D, Flaxel CJ, Glassman AR, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122:375–81.
pubmed: 25439614
doi: 10.1016/j.ophtha.2014.08.047
Massin P, Bandello F, Garweg J, Hansen L, Harding S. Efficacy of ranibizumab in diabetic macular edema (RESOLVE Study*). Diabetes Care. 2010;33:2399–405.
pubmed: 20980427
pmcid: 2963502
doi: 10.2337/dc10-0493
Vujosevic S, Midena E, Pilotto E, Radin PP, Chiesa L, Cavarzeran F. Diabetic macular edema: correlation between microperimetry and optical coherence tomography findings. Investig Ophthalmol Vis Sci. 2006;47:3044–51.
doi: 10.1167/iovs.05-1141
Bonnin S, Tadayoni R, Erginay A, Massin P, Dupas B. Correlation between ganglion cell layer thinning and poor visual function after resolution of diabetic macular edema. Investig Ophthalmol Vis Sci. 2015;56:978–82.
doi: 10.1167/iovs.14-15503
Mendoza-Santiesteban CE, Fernández-Cherkasova L, Echavarria OH, Rodríguez RC, Columbié-Garbey Y, Riesgo TJ. Multifocal electroretinography. Semin Ophthalmol. 2010;25:155–64.
pubmed: 20695736
doi: 10.3109/08820538.2010.500210
Weiner A, Christopoulos VA, Gussler CH, Adams DH, Kaufman SR, Kohn HD, et al. Foveal cone function in nonproliferative diabetic retinopathy and macular edema. Investig Ophthalmol Vis Sci. 1997;38:1443–9.
Drum B, Calogero D, Rorer E. Assessment of visual performance in the evaluation of new medical products. Drug Discov Today Technol. 2007;4:55–61.
pubmed: 24980842
doi: 10.1016/j.ddtec.2007.10.009
Hafner J, Karst S, Schmidt-Erfurth U. Potential imaging biomarkers in the development and progression of diabetic retinopathy. In book: Early events in diabetic retinopathy and intervention strategies. IntechOpen; 2018. p. 9–36.
Diabetic Retinopathy Clinical Research Network, Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology. 2007;114:525–36.
doi: 10.1016/j.ophtha.2006.06.052
Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmol. 2010;117:1064–77.e35.
doi: 10.1016/j.ophtha.2010.02.031
Prünte C, Fajnkuchen F, Mahmood S, Ricci F, Hatz K, Studnička J, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. 2016;100:787–95.
pubmed: 26453639
doi: 10.1136/bjophthalmol-2015-307249
Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA. 2019;321:1880–94.
pubmed: 31037289
pmcid: 6537845
doi: 10.1001/jama.2019.5790
Baget-Bernaldiz M, Romero-Aroca P, Bautista-Perez A, Mercado J. Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumab. Doc Ophthalmol. 2017;135:85–96.
pubmed: 28779336
pmcid: 5606940
doi: 10.1007/s10633-017-9601-2
Comyn O, Sivaprasad S, Peto T, Neveu MM, Holder GE, Xing W, et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). Am J Ophthalmol. 2014;157:960–70.
pubmed: 24531025
doi: 10.1016/j.ajo.2014.02.019
Malagola R, Spinucci G, Cofone C, Pattavina L. Prospective microperimetry and OCT evaluation of efficacy of repeated intravitreal bevacizumab injections for persistent clinically significant diabetic macular edema. Int Ophthalmol. 2013;33:261–7.
pubmed: 23242589
doi: 10.1007/s10792-012-9685-3
Wu Z, Ayton LN, Guymer RH, Luu CD. Comparison between multifocal electroretinography and microperimetry in age-related macular degeneration. Investig Ophthalmol Vis Sci. 2014;55:6431–9.
doi: 10.1167/iovs.14-14407